Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6 (A Poster)
![](https://omnixmedical.com/wp-content/uploads/2021/03/Preventing-the-Spread-of-Germs-This-Flu-Season-scaled-1-1024x576.jpeg)
Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6, a Novel Antimicrobial Peptide for Acinetobacter baumannii (AB), Conducted in Healthy Volunteers Access Full Poster Background Serious Gram-negative bacterial infections, particularly those caused by Acinetobacter baumannii (AB), pose a significant global health threat due to increasing antibiotic resistance (1-2). OMN6 is a novel, biochemically-engineered antimicrobial […]
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
![](https://omnixmedical.com/wp-content/uploads/2021/09/Depositphotos_169779714_l-2015-1024x682.jpg)
Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the Company has received fast-track designation for its novel anti-infective OMN6 from the U.S. Food and Drug Administration (FDA). Fast track expedited […]
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
![](https://omnixmedical.com/wp-content/uploads/2021/03/HarmfulBacteria_web-1024x683.jpeg)
JERUSALEM, Israel, November 20, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has approved a planned Phase II trial of the Company´s novel anti-infective OMN6. The multinational, multicenter trial will assess the safety and pharmacokinetics of OMN6 […]
OMN6 – Omnix Medical’s Lead Antimicrobial Peptide Receives Notice of Allowance from the Indian Patent Office
![](https://omnixmedical.com/wp-content/uploads/2021/09/Depositphotos_169779714_l-2015-1024x682.jpg)
We are here to announce that the Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment of infectious diseases. This pivotal achievement signifies that OMN6, developed with a commitment to revolutionize infectious disease treatment, has met the stringent criteria required for intellectual property protection. Importantly, the […]
Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6
![](https://omnixmedical.com/wp-content/uploads/2021/03/images.jpeg)
OMN6 demonstrates safety and tolerability at clinically significant dose levels JERUSALEM, Israel, May 8th, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced positive top-line results from the Phase I clinical trial of its lead compound OMN6, an anti-infective with a completely novel mechanism of action. […]
RECOGNITION AT EUROPEAN INNOVATION COUNCIL’S INVESTOR DAY
![](https://omnixmedical.com/wp-content/uploads/2021/03/images-1.jpeg)
We are delighted to announce that Dr. Niv Bachnoff, our Chief Scientific Officer, has won the First Prize for Best Presentation in the Biotech & Pharmaceuticals category at the European Innovation Council’s Investor Day on Healthcare, which took place in Lisbon in November, presenting Omnix Medical to Investors and fellow EIC H2020 champions and raising […]
STUDY: In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii
![](https://omnixmedical.com/wp-content/uploads/2021/03/science-background-with-molecule-atom-abstract-structure-science-medical-background-3d-illustration_36845-253.jpeg)
The rapid worldwide spread of antimicrobial resistance (AMR) underscores the significant need for the development of innovative treatments to fight multidrug-resistant bacteria. Our Scientists at Omnix Medical have published a study demonstrating the potent antimicrobial activity of the novel peptide OMN6 against a wide array of drug-resistant Acinetobacter baumannii. Results point to OMN6 as a novel antimicrobial […]
OMNIX MEDICAL ANNOUNCES THE ADDITION OF TWO NEW PEPTIDE FAMILIES – OMN50 AND OMN70
![](https://omnixmedical.com/wp-content/uploads/2021/09/Depositphotos_169779714_l-2015-1024x682.jpg)
Omnix Medical is pleased to announce the addition of two new peptide families – OMN50 and OMN70. At Omnix, we are working hard to build our clinical pipeline with new peptide-based drugs that address broad unmet medical needs. Using Omnix drug discovery platform to screen a wide-ranging array of peptides originating from marine organisms, insects […]
OMNIX MEDICAL STARTS PHASE I CLINICAL TRIAL OF NOVEL ANTI-INFECTIVE; FIRST HEALTHY VOLUNTEERS DOSED
![](https://omnixmedical.com/wp-content/uploads/2021/03/images.jpeg)
New mechanism of action (MoA) addressing global increase of antimicrobial resistance (AMR) burden and shortage of potent anti-infectives JERUSALEM, Israel, April 12, 2022 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced the initiation of a Dutch Phase I clinical trial with its lead compound OMN6. Since […]
OMNIX MEDICAL ADVANCES NOVEL ANTI-INFECTIVE PROGRAM INTO CLINICAL DEVELOPMENT
![](https://omnixmedical.com/wp-content/uploads/2021/03/science-background-with-molecule-atom-abstract-structure-science-medical-background-3d-illustration_36845-253.jpeg)
Entirely novel therapeutic principle to combat alarming worldwide rise of antimicrobial resistance (AMR) JERUSALEM, Israel, March 16, 2022 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced it received approval by Dutch authorities to initiate a Phase I clinical trial with its lead compound OMN6 in healthy […]